Middle return on low investment with low risk taking
One thing that characterize ourselves is that we have a low investment with low risk taking business model.
Only one in 20,000 is the chance of a new drug birth. Though drug development by our own hands may maximize return after commercialization of a new drug, we concentrate our management resources on R&D and focus on discovering candidate drugs. We aim middle return by controlling R&D risk with our own drug discovery technology.
Advance investment period continues
We need to invest in advance to continue R&D activity. We also pay attention to our company’s financial stability and aim to be profitable in near future by discovering nobel drug candidates and advancing clinical stage pipelines.
Milestone disclosure in quarterly bases
Milestone disclosure (available in Japanese) covers status of our clinical stage pipelines and our discovery program.
Discover nobel drug candidates
For continuous growth of our company, it is important to have multiple pipelines. To discover one drug candidate in every 2 to 3 years is our strategic challenge.
In result of the above challenge, we aim to be profitable in near future.
Be a front-runner among biotechnology (bio-venture) companies around the world
With short supply of nobel drug discovery, DWTI is one of few biotechnology (bio-venture) companies, which focuses on drug discovery from very early stage. We continue drug discovery in order to bring innovative drugs to patients in need of unmet medical needs.
